|
| | Azelastine hydrochloride Basic information |
| | Azelastine hydrochloride Chemical Properties |
| Melting point | 225--2290C | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO: >10mg/mL | | form | powder | | color | white to off-white | | Merck | 14,906 | | Stability: | Incompatible with strong oxidizing agents. | | InChI | InChI=1S/C22H24ClN3O.ClH/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16;/h2-3,6-11,18H,4-5,12-15H2,1H3;1H | | InChIKey | YEJAJYAHJQIWNU-UHFFFAOYSA-N | | SMILES | C1(=O)C2=C(C=CC=C2)C(CC2=CC=C(Cl)C=C2)=NN1C1CCCN(C)CC1.[H]Cl | | CAS DataBase Reference | 79307-93-0(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | RTECS | TH9203900 | | HS Code | 2933992600 | | Toxicity | LD50 in male, female mice, male, female rats (mg/kg): 36.5, 35.5, 26.9, 30.3 i.v.; 56.4, 42.8, 43.2, 46.6 i.p.; 63.0, 54.2, 66.5, 59.6 s.c.; 124, 139, 310, 417 orally (Zechel) |
| | Azelastine hydrochloride Usage And Synthesis |
| Description | Azelastine hydrochloride is an orally effective antihistamine useful in the treatment of asthma and nasal allergy. It appears to inhibit release of histamine, in addition to antagonizing its action. | | Chemical Properties | White or almost white, crystalline powder. | | Originator | Asta-Werke(Degussa) (W. Germany) | | Uses | Orally active H1-hystamine receptor antagonist. Antihistaminic | | Definition | ChEBI: The hydrochloride salt of azelastine. | | Brand name | Astelin
(Medpointe); Optivar (Medpointe);AZEPTIN. | | General Description | (±)-4-[(4-chlorophenyl)methyl]-2-(hexahydro-l-methyl-1H-azepin-4-yl)-l-(2H)-phthalazinone monohydrochloride (Optivar), is a whitecrystalline powder that is sparingly soluble in water,methanol, and propylene glycol and slightly soluble inethanol, octanol, and glycerine. The commercial preparationis available as a 0.05% sterile ophthalmic solution fortopical administration to the eyes. Each milliliter of azelastinesolution contains 0.5-mg azelastine hydrochlorideequivalent to 0.457 mg of azelastine base, the preservativebenzalkonium chloride (0.125 mg), and inactive ingredientsincluding disodium edetate dihydrate, hydroxypropylmethylcellulose,sorbitol solution, sodium hydroxide, andwater for injection. The solution has a pH of approximately5.0 to 6.5 and an osmolality of approximately 271to 312 mOsm/L.
The recommended dose of azelastine solution is 1 dropinstilled into each affected eye twice a day. This drugproduct is for ocular administration only and not for injectionor oral use. Absorption of azelastine following ocularadministration is relatively low (less than 1 ng/rnL).Absorbed drug undergoes extensive oxidative N-demethylationby CYP, and the parent drug and metabolite are eliminatedprimarily in the feces. The most frequently reportedadverse reactions are transient eye burning or stinging,headaches, and bitter taste. Azelastine solution should beused with caution during pregnancy or while nursing, becauseits safety has not been studied under these circumstances. | | Biochem/physiol Actions | H1 histamine receptor antagonist; NF-kB activator. | | Safety Profile | Poison by ingestion andintravenous routes. An experimental teratogen. Otherexperimental reproductive effects. When heated todecomposition it emits toxic fumes of NOx and HCl. |
| | Azelastine hydrochloride Preparation Products And Raw materials |
|
